Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn's Disease
he Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path Institute (C-Path) a grant to support a Crohn's disease biomarker pre-consortium. The pre-consortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn's disease.
Currently, a lack of regulatory-endorsed tools, such as biomarkers, hinders the rapid development and approval of improved treatments for Crohn's disease patients. The pre-consortium will focus on identifying Crohn's disease biomarkers and laying the groundwork for future regulatory endorsement. The long-term objective is to fully validate and obtain regulatory qualification of biomarkers, which will enable drug developers and the broader Crohn's disease community of clinicians and researchers to accelerate the development and approval of treatments for those living with this disease.
"At C-Path, we work collaboratively to identify mechanisms to address areas of unmet need. The partnership and support from Helmsley will allow us to define the most effective approach to forming a Crohn's Disease Biomarker Consortium to take forward the best biomarkers into regulatory qualification," said John-Michael Sauer, PhD, C-Path Biomarker Program Officer...